Marinus Pharmaceuticals to Announce Q1 2024 Results on May 8

Marinus Pharmaceuticals, Inc., a company listed on Nasdaq under the ticker symbol MRNS, is devoted to developing cutting-edge treatments for seizure disorders. On May 8, 2024, before the market opens, Marinus plans to disclose its financial results for the first quarter ending March 31, 2024. The press release detailing these results will be accessible on Marinus’ investor relations website.

Marinus Pharmaceuticals is recognized as a commercial-stage pharmaceutical organization focused on creating innovative therapies for seizure-related conditions. In 2022, the company launched ZTALMY® (ganaxolone) oral suspension CV in the United States after receiving FDA approval. This marked a significant milestone as ZTALMY® became a prescription medication aimed at treating seizure disorders.

The company's dedication extends beyond just the initial launch of ZTALMY®. Marinus is continually exploring the potential of ganaxolone in various formulations, including both intravenous (IV) and oral forms. This ongoing investment is aimed at broadening the therapeutic applications of ganaxolone, thereby enhancing treatment options for both adult and pediatric patients. The focus is on providing effective care for both acute and chronic seizure conditions.